1. Home
  2. BTGO vs EVO Comparison

BTGO vs EVO Comparison

Compare BTGO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTGO

BitGo Holdings Inc. Class A Common Stock

N/A

Current Price

$6.05

Market Cap

961.8M

Sector

Finance

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.06

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTGO
EVO
Founded
2013
1993
Country
United States
Germany
Employees
603
4553
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
961.8M
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BTGO
EVO
Price
$6.05
$3.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
1
Target Price
$14.83
$7.00
AVG Volume (30 Days)
1.6M
47.1K
Earning Date
05-13-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$34.41
$10.05
P/E Ratio
$10.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.42
$2.31
52 Week High
$15.30
$4.42

Technical Indicators

Market Signals
Indicator
BTGO
EVO
Relative Strength Index (RSI) 28.11 56.03
Support Level N/A $2.88
Resistance Level $12.40 $3.75
Average True Range (ATR) 0.89 0.07
MACD -0.48 0.01
Stochastic Oscillator 8.32 89.58

Price Performance

Historical Comparison
BTGO
EVO

About BTGO BitGo Holdings Inc. Class A Common Stock

BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: